Cost-Effectiveness of a Herpes Zoster Vaccination Program among the French Elderly People
2016
This study reports on a cost-effectiveness analysis of herpes zoster (HZ) vaccines among the elderly in France. Starting vaccination in individuals aged 65, 70 and 75 years old appears more cost-effective than vaccination for beginning vaccination at age 60, with a cost-effectiveness ratio between 30,000 and 35,000 euros per quality-adjusted-life year (QALY) gained for the 65 and 70-year age groups versus 54,500 euros for the age 75 group. These results largely contributed to the recommendation to include the HZ vaccination in the French immunization schedule for people aged between 65 and 74 years in France.
Note: This article was published before the release of the newer herpes zoster subunit (HZ/su) vaccine.
Cost-Effectiveness of a Herpes Zoster Vaccination Program among the French Elderly People
Source:
Belchior E, Lévy-Bruhl D, Le Strat Y et al. Cost-Effectiveness of a Herpes Zoster Vaccination Program among the French Elderly People. Human Vaccines & Immunotherapeutics 2016; 12 (9): 2378-2382. https://doi.org/10.1080/21645515.2016.1184801